Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...

Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ...

New medicines, access to treatments, infectious disease monitoring, and more are on the table.View on euronews ...

Despite this, India faces significant challenges in ensuring the development, affordability, and accessibility of orphan ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Following a three-hour hearing, European lawmakers opted on Wednesday night to defer their decision on Olivér Várhelyi's nomination as EU Commissioner for health and animal Welfare, questioning his ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...

Countries aspiring to join the EU have significant work ahead to meet the bloc’s health standards, which involve aligning ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

In 2023/24, the EU launched the Critical Medicines Alliance, while the European Medicines Agency has launched a “solidarity mechanism” for countries to cooperate on shortages. On 18 July 2024, the ...